Free tool
FAERS Monitor: Ddavp
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019955 or its brand name (Ddavp, Desmopressin Acetate). Reports on generic versions are filed under their own applications.
Reports
3,313
Serious
2,397
72% of reports
Hospitalization
1,304
Death reported
238
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hyponatraemia339
- drug ineffective221
- headache191
- nausea181
- fatigue145
- off label use143
- vomiting138
- dizziness117
- diarrhoea110
- pain105
- asthenia98
- malaise87
- pyrexia86
- dyspnoea84
- fall83
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 80 |
| 2005 | 63 |
| 2006 | 75 |
| 2007 | 48 |
| 2008 | 143 |
| 2009 | 147 |
| 2010 | 141 |
| 2011 | 138 |
| 2012 | 167 |
| 2013 | 100 |
| 2014 | 135 |
| 2015 | 133 |
| 2016 | 183 |
| 2017 | 173 |
| 2018 | 166 |
| 2019 | 144 |
| 2020 | 152 |
| 2021 | 172 |
| 2022 | 196 |
| 2023 | 189 |
| 2024 | 255 |
| 2025 | 195 |
| 2026 | 118 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,846 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hyponatraemiaSignal | 339 | 38.4 | 34.7 | 12,283 |
| headache | 191 | 1.9 | 1.7 | 88 |
| vomiting | 138 | 1.9 | 1.6 | 56 |
| asthenia | 98 | 1.7 | 1.4 | 25 |
| fall | 83 | 1.6 | 1.3 | 18 |
| pyrexia | 86 | 1.6 | 1.3 | 18 |
| dizziness | 117 | 1.5 | 1.2 | 19 |
| nausea | 181 | 1.5 | 1.3 | 26 |
| malaise | 87 | 1.3 | 1.0 | 4 |
| fatigue | 145 | 1.2 | 1.0 | 4 |
| pain | 105 | 1.1 | 0.9 | 1 |
| diarrhoea | 110 | 1.1 | 0.9 | 1 |
| drug ineffective | 221 | 1.1 | 0.9 | 1 |
| off label use | 143 | 1.0 | 0.9 | 0 |
| dyspnoea | 84 | 0.9 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.